Drug Approval | October 09, 2023
Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Advances clinical research capabilities with leading regulatory grade registries platform
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Subscribe To Our Newsletter & Stay Updated
